Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in request metadata) on August 6, 2014. The report covers two primary events: the announcement of financial results for the second quarter of 2014 (issued August 7, 2014) and the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the Q2 2014 financial results but does not explicitly state specific values for revenue, profit, cash flow, margins, debt, or liquidity within the text of this 8-K. The document states that the information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Material Changes and Executive Appointment
The most significant material change reported is the appointment of John Bencich as Vice President and Chief Financial Officer, effective August 11, 2014. Mr. Bencich will also serve as the principal financial and accounting officer. He previously served as CFO of Integrated Diagnostics Inc. and Allozyne, Inc.
Compensation and Employment Terms
- Base Salary: $300,000 annually.
- Annual Bonus: Up to 30% of base salary, contingent on corporate milestones.
- Signing Bonus: One-time payment of $20,000.
- Equity Grant: Options to purchase 40,000 shares (vesting monthly over 4 years) and 20,000 restricted stock units (vesting annually over 4 years).
- Severance (Involuntary Termination): 9 months of base salary, 9 months of health insurance, and acceleration of 9 months of equity vesting.
- Change of Control Severance: 12 months of base salary plus 12 months of average bonus, 12 months of health insurance, and immediate vesting of all unvested equity.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2014 revenue, net loss, and cash position figures, as they are not detailed in the 8-K text.
- Verify the impact of the new CFO's compensation package on the company's cash burn rate and equity dilution.
- Confirm the status of the company's principal executive offices and any potential changes in corporate strategy following the leadership transition.
- Check for any subsequent filings regarding the "furnished" financial data to ensure it is incorporated into future 10-Q or 10-K reports.